% | $
Quotes you view appear here for quick access.

Amicus Therapeutics, Inc. Message Board

  • jhamreturns jhamreturns Mar 4, 2013 8:00 AM Flag

    Amicus Therapeutics Introduces Proprietary "CHART" Platform Technology

    New Platform Designation Reflects Development Strategy and Emphasis on Next-Generation Enzyme Replacement Therapies for Lysosomal Storage Diseases.

    March 04, 2013 07:30 | Source: Amicus Therapeutics, Inc.
    CRANBURY, N.J., March 4, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today introduced Chaperone-Advanced Replacement Therapy (CHARTâ„¢) as the brand name for its technology platform that combines unique pharmacological chaperones with enzyme replacement therapy (ERT) for lysosomal storage diseases.

    John F. Crowley, Chairman and Chief Executive Officer of Amicus stated, "We are pleased to introduce CHART as the brand name and designation for our chaperone-ERT combination platform. CHART reflects the breadth of the opportunities at Amicus to develop chaperones co-administered with marketed ERTs, or co-formulated with proprietary enzymes as next-generation ERTs. It is a platform that has already demonstrated proof of concept in the clinic and in multiple pre-clinical studies. The direct co-formulation of our proprietary enzymes with specific small molecule chaperone stabilizers may improve treatment outcomes, reduce immunological responses and potentially enable more convenient delivery routes with these next-generation ERTs. Our strategic vision is to build out this CHART platform to deliver new benefits for patients and create multiple sources of value for our shareholders. This platform will indeed chart a course to a very bright future for Amicus."

    See the PR for the rest of the article.

    Chaperone-Advanced Replacement Therapy (CHART)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
7.57+0.42(+5.87%)Oct 20 4:00 PMEDT